Zoetis

Zoetis Inc. (NYSE: ZTS) is a leading global animal health company headquartered in Parsippany, New Jersey. It discovers, develops, manufactures, and commercializes vaccines, medicines, diagnostics, biopharmaceuticals, and digital solutions for companion animals and livestock, taking an integrated approach to building a diverse and durable product portfolio. Product categories span vaccines, parasiticides, anti-infectives, diagnostics, and medicated feed additives.

The company supports core species including dogs, cats, horses, cattle (beef and dairy), swine, poultry, fish, and sheep. Zoetis markets products directly in approximately 45 countries and distributes in more than 100 countries worldwide, operating manufacturing facilities and research centers across 28 sites in 11 countries.

Originally established as Pfizer's Agriculture Division in 1952, the business operated as Pfizer Animal Health (from 1988) before completing its IPO on February 1, 2013, and becoming fully independent that year. Kristin Peck has served as CEO since January 2020, succeeding founding CEO Juan Ramón Alaix.

For full year 2024, Zoetis reported revenue of $9.3 billion (up 8% year over year) and net income of $2.5 billion, or $5.47 per diluted share, with adjusted net income of $2.7 billion. Its 2024 sales led the global animal health market ahead of competitors such as Boehringer Ingelheim and Merck. As a science-driven leader emphasizing biopharmaceuticals, diagnostics, and digital solutions, innovation is central to its business and competitive position.